Efficacy of agents counteracting hypoxia in fractionated radiation regimes

Radiotherapy and Oncology

Volumn 41, Issue 2, 1996, Pages 143-149

  Stern, Sabine ^a   Guichard, Marcelle ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

carbogen; fractionated irradiation; hypoxia; nicotinamide; perflubron emulsion; tirapazamine

Indexed keywords

CARBOGEN; NICOTINAMIDE; PERFLUOROOCTYL BROMIDE; TIRAPAZAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPOXIA; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIZATION;

ADENOCARCINOMA; ANIMALS; CARBON DIOXIDE; CELL HYPOXIA; EMULSIONS; FEMALE; FLUOROCARBONS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NIACINAMIDE; OXYGEN; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RECTAL NEOPLASMS; TRIAZINES; TUMOR CELLS, CULTURED;

EID: 0030294383     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(96)01787-2     Document Type: Article

References (42)

1. [1] Brizel, D.M., Dodge, R. and Dewhirst, M.W. The effect of the perflubron emulsion Oxygent™ on the calibration characteristics of polaragraphic oxygen electrodes. Radiother. Oncol. 33: 262-265, 1994.
2. [2] Brown, J.M. and Lemmon, M.J. Potentiation by the hypoxic cytotoxin SR4233 of cell killing produced by fractionated irradiation of mouse tumors. Cancer Res. 50: 7745-7749, 1990.
3. [3] Brown, J.M. and Lemmon, M.J. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes. Radiother. Oncol. Suppl. 20: 151-156, 1991.
4. [4] Brown, J.M. and Lemmon, M.J. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation. Int. J. Radiat. Oncol. Biol. Phys. 20: 457-461, 1991.
5. [5] Brown, J.M. and Lemmon, M.J. Fractionation increases the anti-tumor effect of adding a hypoxic cytotoxin to irradiation. In: Radiation Research, A Twentieth-Century Perspective, pp. 807-812. Editors: W.C. Dewey, M. Edington, R.J.M. Fry, E.J. Hall and G.F. Whitmore. Academic Press Inc., San Diego, 1991.
6. [6] Brown, J.M. SR4233 (Tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer 67: 1163-1170, 1993.
7. [7] Bruneton, J.N., Falewée, M.N., François, E., Cambon, P., Philip, C., Riess, J.G., Balu-Maestro, C. and Rogopoulos, A. Liver, spleen, and vessels: preliminary clinical results of CT with perfluorooctylbromide. Radiology 170: 179-183, 1989.
8. [8] Calcutt, G., Ting, S.M. and Preece, A.W. Tissue NAD levels and the response to irradiation or cytotoxic drugs. Br. J. Cancer 24: 380-388, 1970.
9. [9] Chaplin, D.J., Horsman, M.R. and Trotter, M.J. Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor. J. Natl. Cancer Inst. 82: 672-676, 1990.
10. [10] Chaplin, D.J., Horsman, M.R. and Aoki, D.S. Nicotinamide, Fluosol DA and carbogen: a strategy to reoxygenate acutely and chronically hypoxic cell in vivo. Br. J. Cancer 63: 109-113, 1991.
11. [11] Chaplin, D.J. Acute hypoxia in tumors; implications for modifiers of radiation effects. Int. J. Radiat. Oncol. Biol. Phys. 12: 1279-1282, 1986.
12. [12] Chapman, J.D. Measurement of tumor hypoxia by invasive and non-invasive procedures: a review of recent clinical studies. Radiother. Oncol. Suppl. 20: 13-19, 1991.
13. [13] Doherty, N., Hancock, S.L., Kaye, S., Coleman, C.N., Shulman, L., Marquez, C., Mariscal, C., Rampling, R., Senan, S. and Roemeling, R.V. Muscle cramping in phase I clinical trials of tirapazamine (SR4233) with and without radiation. Int. J. Radiat. Oncol. Biol. Phys. 29: 379-382, 1994.
14. [14] Dorie, M.J., Menke, D. and Brown, J.M. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen. Int. J. Radiat. Oncol. Biol. Phys. 28: 145-150, 1993.
15. [15] Guichard, M., Lachet, B. and Malaise, E.P. Measurement of RBE, OER and recovery of potentially lethal damage of a 645 MeV helium ion beam using EMT6 cells. Radiat. Res. 71: 413-420, 1977.
16. [16] Guichard, M., Dertinger, H. and Malaise, E.P. Radiosensitivity of four human tumor xenografts. Influence of hypoxia and cell-cell contact. Radiat. Res. 95: 602-609, 1983.
17. [17] Guichard, M. and Lartigau, E. New trends for improving radiation sensitivity by counteracting chronic and acute hypoxia. Adv. Radiat. Biol. 18: 123-147, 1994.
18. 2 tension measurements. Cancer Res. 51: 6098-6102, 1991.
19. [19] Horsman, M.R., Brown, J.M., Hirst, V.K., Lemmon, M.J., Wood, P.J., Dunphy, E.P. and Overgaard, J. Mechanism of action of the selective tumor radiosensitizer nicotinamide. Int. J. Radiat. Oncol. Biol. Phys. 15: 685-690, 1988.
20. [20] Horsman, M.R., Chaplin, D.J. and Brown, J.M. Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat. Res. 118: 139-150, 1989.
21. [21] Horsman, M.R., Hoyer, M., Honess, D.J., Dennis, I.F. and Overgaard, J. Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother. Oncol. 27: 131-139, 1993.
22. [22] Kjellen, E., Joiner, M.C., Collier, J.M., Johns, H. and Rojas, A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother. Oncol. 22: 81-91, 1991.
23. [23] Lambin, P., Guichard, M., Chavaudra, N. and Malaise, E.P. The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity. Radiother. Oncol. 24: 201-204, 1992.
24. [24] Lartigau, E. and Guichard, M. The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours. Br. J. Cancer 73: 1480-1485, 1996.
25. [25] Moulder, J.E. and Rockwell, S. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. Int. J. Radiat. Oncol. Biol. Phys. 10: 695-712, 1984.
26. [26] Riess, J.G., Dalfors, J.L., Hanna, G.K., Klein, D.H., Krafft, M.P., Pelura, T.J. and Schutt, E.G. Development of highly fluid, concentrated and stable fluorocarbon emulsions for diagnosis and therapy. Biomat. Art. Cells Immob. Biotech. 20: 839-842, 1992.
27. [27] Riess, J.G. Highly fluorinated systems for oxygen transport, diagnosis and drug delivery. Colloids Surfaces A: Physicochem. Eng. Aspects 84: 33-48, 1994.
28. [28] Rockwell, S. and Moulder, J.E. Hypoxic fractions of human tumors xenografted into mice: a review. Int. J. Radiat. Oncol. Biol. Phys. 19: 197-202, 1990.
29. [29] Rockwell, S., Kelley, M., Irvin, C.G., Hughes, C.S., Porter, E., Yabuky, H. and Fischer, J. Modulation of tumor oxygenation and radiosensitivity by a perfluorooctylbromide emulsion. Radiother. Oncol. 22: 92-98, 1991.
30. [30] Rojas, A., Hodgkiss, R.J., Stratford, M.R.L., Dennis, M.F. and Johns, H. Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations. Br. J. Cancer 68: 1115-1121, 1993.
31. [31] Simon, J.M., Lartigau, E. and Guichard, M. Nicotinamide and carbogen: major effect on the radiosensitivity of EMT6 and HRT18 tumours. Radiother. Oncol. 28: 203-207, 1993.
32. [32] Stern, S., Hodgkiss, R.J. and Guichard, M. Comparison of two techniques for detecting tumour hypoxia: a fluorescent immunochemical method and an in vitro colony assay. Radiother. Oncol. 39: 129-135, 1996.
33. [33] Teicher, B.A., Herman, T.S. and Jones, S.M. Influence of schedule dose, and volume of administration of perfluorochemical emulsion on tumor response to radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 19: 945-951, 1990.
34. [34] Teicher, B.A., Sotomayor, E.A., Dupuis, N.P., Kusumoto, T. and Menon, K. Reduced oxygenation in a rat mammary carcinoma after chemo-or radiation therapy and reoxygenation with perflubron emulsion/carbogen breathing. J. Cancer Res. Clin. Oncol. 120: 593-598, 1994.
35. 2 measurements in one rodent and two human tumor xenografts, Radiat. Res. 139: 1-8, 1994.
36. [36] Thomas, C.D., Prade, M. and Guichard, M. Tumour oxygenation, radiosensitivity, and necrosis before and/or after nicotinamide, carbogen and perflubron emulsion administration. Int. J. Radiat. Biol. 67: 597-606, 1995.
37. [37] Thomas, C., Riess, J. and Guichard, M. Influence of the 100% w/v perfluorooctyl bromide (PFOB) emulsion dose on tumour radiosensitivity. Int. J. Radiat. Biol. 59: 433-445, 1991.
38. [38] Trotter, M.J., Chaplin, D.J., Durand, R.E. and Olive, P.L. The use of fluorescent probes to identify regions of transient perfusion in murine tumors. Int. J. Radiat. Oncol. Biol. Phys. 16: 931-934, 1989.
39. [39] Vaupel, P. Oxygenation of human tumors. Strahlenther Onkol. 166: 377-386, 1990.
40. [40] Vitu-Loas, L., Thomas, C., Chavaudra, N. and Guichard, M. Radiosensitivity, blood perfusion and tumour oxygenation after perflubron emulsion injection. Radiother. Oncol. 27: 149-155, 1993.
41. [41] Zeman, E.M., Brown, J.M., Lemmon, M.J., Hirst, V.K. and Lee, W.W. SR4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys. 12: 1239-1242, 1986.
42. [42] Zeman, E.M., Hirst, V.K., Lemmon, M.J. and Brown, J.M. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR4233. Radiother. Oncol. 12: 209-218, 1988.